The Centers for Disease Control and Prevention (CDC) have released a report about the effectiveness of Pfizer-BioNTech mRNA vaccination against COVID-19 hospitalization among persons aged 12–18 years.

The findings in the report suggested that among hospitalized U.S. patients aged 12–18 years, vaccine effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization during June–September 2021, was 93% (95% confidence interval = 83%–97%).

Key evaluation from the report demonstrated that 2 doses of Pfizer-BioNTech vaccine were highly effective in preventing COVID-19 hospitalization among persons aged 12–18 years, reinforcing the importance of vaccination to protect U.S. youths against severe COVID-19.

To read the report in full, please click on the link below.
CDC: Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years

MVEC acknowledges the traditional owners of the lands on which we live, work and educate. We pay our respects to their Elders, past, present and emerging.
We are committed to honouring Australian Aboriginal and Torres Strait Islander peoples’ unique cultural and spiritual relationships to the land, waters and seas.

关于 MVEC

墨尔本疫苗教育中心 (MVEC) 是一个教育网站,旨在为医疗保健专业人员和公众提供最新的免疫接种信息。我们位于研究机构默多克儿童研究所 (MCRI),隶属于维多利亚疫苗安全服务机构 SAEFVIC(社区接种疫苗后的不良事件监测)。

分享这个